@US10 silence since XanaHES announcement, page-10

i am meeting with bill on melbourne cup day - ill press him to go for a consolidation to rid us of or at least disincline the DT’s.
further , a share price above 20c with so much less volume on issue is more attractive to the institutional investor particularly those offshore.
i ll report back on his thinking in the matter - im all for a 5or 7 to one - lets see
any thoughts on the matter guys or indeed specific non sensitive questions you might want answered?
after the melb bio conf and short 11 minute video interview , Bill i think inferred the rest of the data from the 20 millg trial on healthy elderly patients will be made available sometime before year end
at least thats how i interpreted it
really looking forward to the consolidated data and the setting out of the strategic plan going ahead next year fully funded.
interesting how he noted that the just finished trial wasnt that expensive and there is more than enough funds to service two more similar trials next year
personally given toxicity seems not to be an isdue id like to see a trisl of 30 millg or twice a day of 20 mg each.
by then the sp should ( i hope and muse of course) be a lot higher thereby offsetting the dilutionary impact of a cap raise
a 1 for 7 consolidation next year would help, i believe drive the appetite for the stock as well